SNDL Past Earnings Performance
Past criteria checks 0/6
SNDL's earnings have been declining at an average annual rate of -5.3%, while the Pharmaceuticals industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 61.4% per year.
Key information
-5.3%
Earnings growth rate
63.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 61.4% |
| Return on equity | -9.4% |
| Net Margin | -12.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How SNDL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 912 | -113 | 224 | 0 |
| 31 Mar 24 | 916 | -136 | 228 | 0 |
| 31 Dec 23 | 909 | -168 | 230 | 0 |
| 30 Sep 23 | 901 | -211 | 221 | 1 |
| 30 Jun 23 | 894 | -287 | 213 | 2 |
| 31 Mar 23 | 886 | -331 | 196 | 2 |
| 31 Dec 22 | 712 | -335 | 158 | 2 |
| 30 Sep 22 | 495 | -266 | 124 | 3 |
| 30 Jun 22 | 278 | -151 | 88 | 2 |
| 31 Mar 22 | 64 | -130 | 60 | 2 |
| 31 Dec 21 | 56 | -227 | 55 | 2 |
| 30 Sep 21 | 47 | -228 | 50 | 2 |
| 30 Jun 21 | 46 | -316 | 49 | 1 |
| 31 Mar 21 | 57 | -296 | 45 | 0 |
| 31 Dec 20 | 61 | -200 | 46 | 0 |
| 30 Sep 20 | 62 | -170 | 59 | 1 |
| 30 Jun 20 | 77 | -184 | 70 | 1 |
| 31 Mar 20 | 76 | -164 | 80 | 3 |
| 31 Dec 19 | 64 | -143 | 86 | 2 |
| 30 Sep 19 | 49 | -156 | 72 | 2 |
| 30 Jun 19 | 21 | -84 | 54 | 2 |
| 31 Mar 19 | 1 | -77 | 37 | 0 |
| 31 Dec 18 | 0 | -68 | 22 | 0 |
| 28 Feb 18 | 0 | -13 | 9 | 0 |
Quality Earnings: VY4 is currently unprofitable.
Growing Profit Margin: VY4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VY4 is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare VY4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VY4 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: VY4 has a negative Return on Equity (-9.4%), as it is currently unprofitable.